TY - JOUR
T1 - Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
AU - Kerner, Gerald S. M. A.
AU - van Dullemen, Leon F. A.
AU - Wiegman, Erwin M.
AU - Widder, Joachim
AU - Blokzijl, Edwin
AU - Driever, Ellen M.
AU - van Putten, John W. G.
AU - Liesker, Jeroen J. W.
AU - Renkema, Tineke E. J.
AU - Pieterman, Remge M.
AU - Mertens, Marc J. F.
AU - Hiltermann, Thijo J. N.
AU - Groen, H.J.M.
PY - 2014/8/29
Y1 - 2014/8/29
N2 - Background: Stage III unresectable non-small cell lung cancer (NSCLC) is preferably treated with concurrent schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that has been studied in phase 1 and 2 studies in this setting. The aim of this study was to describe outcome and toxicity of low-dose weekly gemcitabine combined with concurrent 3-dimensional conformal radiotherapy (3D-CRT).Patients & methods: Treatment consisted of two cycles of a cisplatin and gemcitabine followed by weekly gemcitabine 300 mg/m(2) during 5 weeks of 3D-CRT, 60 Gy in 5 weeks (hypofractionated-accelerated). Overall survival (OS), progression-free survival (PFS), and treatment related toxicity according to Common Toxicity Criteria of Adverse Events (CTCAE) version 3.0 were assessed.Results: Between February 2002 and August 2008, 318 patients were treated. Median age was 64 years (range 36-86); 72% were male, WHO PS 0/1/2 was 44/53/3%. Median PFS was 15.5 months (95% confidence interval [CI], 12.9-18.1) and median OS was 24.6 months (95% CI., 21.0-28.1). Main toxicity (CTCAE grade >= 3) was dysphagia (12.6%), esophagitis (9.6%), followed by radiation pneumonitis (3.0%). There were five treatment related deaths (1.6%), two due to esophagitis and three due to radiation pneumonitis.Conclusion: Concurrent low-dose gemcitabine and 3D-CRT provides a comparable survival and toxicity profile to other available treatment schemes for unresectable stage III.
AB - Background: Stage III unresectable non-small cell lung cancer (NSCLC) is preferably treated with concurrent schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that has been studied in phase 1 and 2 studies in this setting. The aim of this study was to describe outcome and toxicity of low-dose weekly gemcitabine combined with concurrent 3-dimensional conformal radiotherapy (3D-CRT).Patients & methods: Treatment consisted of two cycles of a cisplatin and gemcitabine followed by weekly gemcitabine 300 mg/m(2) during 5 weeks of 3D-CRT, 60 Gy in 5 weeks (hypofractionated-accelerated). Overall survival (OS), progression-free survival (PFS), and treatment related toxicity according to Common Toxicity Criteria of Adverse Events (CTCAE) version 3.0 were assessed.Results: Between February 2002 and August 2008, 318 patients were treated. Median age was 64 years (range 36-86); 72% were male, WHO PS 0/1/2 was 44/53/3%. Median PFS was 15.5 months (95% confidence interval [CI], 12.9-18.1) and median OS was 24.6 months (95% CI., 21.0-28.1). Main toxicity (CTCAE grade >= 3) was dysphagia (12.6%), esophagitis (9.6%), followed by radiation pneumonitis (3.0%). There were five treatment related deaths (1.6%), two due to esophagitis and three due to radiation pneumonitis.Conclusion: Concurrent low-dose gemcitabine and 3D-CRT provides a comparable survival and toxicity profile to other available treatment schemes for unresectable stage III.
KW - Gemcitabine
KW - Stage III NSCLC
KW - Radiotherapy
KW - Concurrent chemoradiotherapy
KW - RANDOMIZED PHASE-III
KW - INDUCTION CHEMOTHERAPY
KW - CONSOLIDATION DOCETAXEL
KW - THORACIC RADIOTHERAPY
KW - ONCOLOGY-GROUP
KW - I TRIAL
KW - RADIATION
KW - CHEMORADIATION
KW - CARBOPLATIN
KW - PACLITAXEL
U2 - 10.1186/1748-717X-9-190
DO - 10.1186/1748-717X-9-190
M3 - Article
C2 - 25174943
SN - 1748-717X
VL - 9
JO - Radiation oncology
JF - Radiation oncology
M1 - 190
ER -